Obseva (OBSV) Announces Quarterly Earnings Results

Share on StockTwits

Obseva (NASDAQ:OBSV) announced its quarterly earnings results on Thursday. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.04, Morningstar.com reports.

Shares of Obseva stock traded down $0.57 on Friday, reaching $15.35. 26,596 shares of the company were exchanged, compared to its average volume of 137,080. The stock has a market capitalization of $584.80 million, a price-to-earnings ratio of -6.82 and a beta of 1.75. Obseva has a 1-year low of $9.05 and a 1-year high of $20.35.

A number of brokerages have recently weighed in on OBSV. Zacks Investment Research upgraded Obseva from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Thursday, October 18th. HC Wainwright set a $44.00 price target on Obseva and gave the stock a “buy” rating in a research report on Monday, October 15th. TheStreet upgraded Obseva from a “d+” rating to a “c-” rating in a research report on Thursday, October 11th. Wedbush set a $34.00 price target on Obseva and gave the stock a “buy” rating in a research report on Wednesday, October 3rd. Finally, JPMorgan Chase & Co. began coverage on Obseva in a research report on Thursday, September 13th. They set an “overweight” rating and a $29.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average price target of $29.43.

Institutional investors have recently made changes to their positions in the company. DRW Securities LLC raised its position in shares of Obseva by 55.0% during the 2nd quarter. DRW Securities LLC now owns 33,812 shares of the company’s stock worth $512,000 after purchasing an additional 12,000 shares during the period. Vivo Capital LLC bought a new position in Obseva in the 2nd quarter worth approximately $14,005,000. Point72 Asset Management L.P. bought a new position in Obseva in the 2nd quarter worth approximately $3,028,000. Laurion Capital Management LP bought a new position in Obseva in the 2nd quarter worth approximately $2,271,000. Finally, US Bancorp DE bought a new position in Obseva in the 2nd quarter worth approximately $197,000. Institutional investors and hedge funds own 68.33% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Obseva (OBSV) Announces Quarterly Earnings Results” was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://baseballnewssource.com/2018/11/10/obseva-obsv-announces-quarterly-earnings-results/2973411.html.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Read More: Book Value Per Share in Stock Trading

Earnings History for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.